Esterified Estrogens & Methyltestosterone Tablets, USP 0.625 mg/1.25 mg, 100-count bottles, Rx O...
FDA Drug Recall #D-1438-2019 — Class III — September 25, 2017
Recall Summary
| Recall Number | D-1438-2019 |
| Classification | Class III — Low risk |
| Date Initiated | September 25, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Amneal Pharmaceuticals, Inc. |
| Location | Brookhaven, NY |
| Product Type | Drugs |
| Quantity | 19104 units |
Product Description
Esterified Estrogens & Methyltestosterone Tablets, USP 0.625 mg/1.25 mg, 100-count bottles, Rx Only, Manufactured by: Ammeal Pharmaceuticals of NY Hauppauge, NY 11788 Distributed by: Seton Pharmaceuticals Manasquan, NJ 08736, NDC 13925-171-01
Reason for Recall
Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.
Distribution Pattern
Nationwide within the United States
Lot / Code Information
Lot #: HL05715, HL05815, Exp. 11/2017
Other Recalls from Amneal Pharmaceuticals, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0613-2020 | Class II | Ranitidine Tablets, USP 300 mg - a).30-count bo... | Nov 22, 2019 |
| D-0616-2020 | Class II | Ranitidine Tablets, USP 300 mg, 250-count bottl... | Nov 22, 2019 |
| D-0612-2020 | Class II | Ranitidine Tablets, USP 150 mg a).60-count bot... | Nov 22, 2019 |
| D-0615-2020 | Class II | Ranitidine Tablets, USP 150 mg, 1000-count bott... | Nov 22, 2019 |
| D-0614-2020 | Class II | Ranitidine Syrup Oral Solution 15 mg/mL 6. fl. ... | Nov 22, 2019 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.